Lien S, Lowman H B
Antibody Engineering, Protein Engineering, and Immunology Departments, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Handb Exp Pharmacol. 2008(181):131-50. doi: 10.1007/978-3-540-73259-4_6.
Vascular endothelial growth factor (VEGF-A) is a key cytokine in the development of normal blood vessels as well as the development of vessels in tumors and other tissues undergoing abnormal angiogenesis. Here, we review the molecular engineering of two humanized antibodies derived from a common mouse anti-VEGF antibody--bevacizumab, a full-length IgG1 approved for the treatment of specified cancer indications, and ranibizumab, an affinity-matured antibody Fab domain approved for use in age-related macular degeneration (AMD). In clinical trials and as FDA-approved therapeutics, these two anti-VEGF antibodies, bevacizumab (Avastin anti-VEGF antibody) and ranibizumab (Lucentis anti-VEGF antibody), have demonstrated therapeutic utility in blocking VEGF-induced angiogenesis.
血管内皮生长因子（VEGF - A）是正常血管发育以及肿瘤和其他经历异常血管生成的组织中血管发育的关键细胞因子。在此，我们综述了两种源自常见小鼠抗VEGF抗体的人源化抗体的分子工程——贝伐单抗，一种被批准用于治疗特定癌症适应症的全长IgG1；以及雷珠单抗，一种被批准用于年龄相关性黄斑变性（AMD）的亲和力成熟的抗体Fab结构域。在临床试验和作为FDA批准的治疗药物中，这两种抗VEGF抗体，即贝伐单抗（阿瓦斯汀抗VEGF抗体）和雷珠单抗（雷珠单抗抗VEGF抗体），已证明在阻断VEGF诱导的血管生成方面具有治疗效用。
